Protium Science is a South Korean specialist offering contract development and analysis (CDAO) and contract development and manufacturing (CDMO) services, spanning cell line and culture process development through API and finished-product manufacturing. The company also provides consulting and document preparation services required for clinical trial applications. It recently completed development of analytical methods for peptide therapeutics, including GLP-1, and for antibody-drug conjugates (ADCs), and has begun offering those services. Protium is a subsidiary of Tiumbio, a company listed on the KOSDAQ and engaged in new drug development. The business has entered a partnership with HK innoN to leverage both parties' technologies and expertise. The collaboration is positioned to generate synergies and support future expansion and acceleration of biopharmaceutical pipeline development within the broader group.

Total raised

$1M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2024